Alaunos Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5,000 | $10,000 | $5,000 | $2.9M | $398,000 |
| Research and development | $1.4M | $362,000 | $16.3M | $25.0M | $49.6M |
| Operating expenses | $4.2M | $4.8M | $34.3M | $38.0M | $77.9M |
| Operating income | -$4.2M | -$4.8M | -$34.3M | -$35.1M | -$77.5M |
| Interest expense | — | $0 | $1.9M | $3.2M | $1.2M |
| Income tax expense | $0 | — | — | — | — |
| Net income | -$4.2M | -$4.7M | -$4.7M | -$37.7M | -$78.8M |
| Balance Sheet | |||||
| Cash and equivalents | $1.4M | $1.1M | $6.1M | $39.1M | $76.1M |
| Current assets | $2.0M | $2.8M | $8.3M | $53.8M | $78.8M |
| Total assets | $3.0M | $2.8M | $8.3M | $64.9M | $94.9M |
| Current liabilities | $813,000 | $692,000 | $2.0M | $24.2M | $16.0M |
| Total liabilities | $813,000 | $692,000 | $2.0M | $26.4M | $36.8M |
| Total debt | — | — | — | $16.8M | $24.1M |
| Stockholders' equity | $2.2M | $2.1M | $6.3M | $38.6M | $58.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$2.9M | -$5.0M | -$30.1M | -$29.2M | -$61.5M |
| Depreciation and amortization | $7,000 | $2,000 | $2.3M | $2.8M | $2.6M |
| Stock-based compensation | $796,000 | $435,000 | $2.8M | $3.5M | $10.8M |
| Capital expenditure | $98,000 | $0 | $197,000 | $216,000 | $3.3M |
| Free cash flow | -$3.0M | -$5.0M | -$30.3M | -$29.4M | -$64.8M |
| Share repurchases | — | — | $0 | $45,000 | $0 |
| Impairments | — | $0 | $4.8M | $0 | $740,000 |
Shares outstanding 24.4M · Free float 57.2%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.